This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300)	<p>Mouse and cell culture studies suggest CBP and p300 agonists could be useful for improving cognitive function. In cell culture, a small molecule activator of the histone/lysine acetyltransferases CBP and p300 formulated in a carbon nanoparticle penetrated into cells and increased histone acetylation compared with vehicle. In mice, intraperitoneal injection of the nanoparticle-formulated CBP and p300 activator increased neurogenesis, duration of memory and histone acetylation levels in the frontal cortex compared with injection of nanoparticle alone. Next steps include testing the compound in mouse models for neurodegenerative disorders including Alzheimer's disease (AD).</p> <p>SciBX 6(28); doi:10.1038/scibx.2013.732 Published online July 25, 2013</p>	Patent pending; licensing status undisclosed	<p>Chatterjee, S. <i>et al. J. Neurosci.</i>; published online June 26, 2013; doi:10.1523/JNEUROSCI.5772-12.2013 Contact: Anne-Laurence Boutillier, University of Strasbourg, Strasbourg, France e-mail: laurette@unistra.fr Contact: Tapas K. Kundu, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, India e-mail: tapas@jncasr.ac.in</p>